Carolyn F Deacon

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 9

Top Topics

Diffusion Weighted Imaging

Randomized Controlled Trial

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

Nature reviews. Endocrinology

This page only lists publications with an associated author ORCID identifier.

Publications

Nicolai J Wewer Albrechtsen, Andreas Møller, Christoffer Martinussen, Lise L Gluud, Elias B Rashu, Michael M Richter, Peter Plomgaard, Jens P Goetze, Sasha Kjeldsen, Lasse Holst Hansen, Finn Gustafsson, Carolyn F Deacon, Jens J Holst, Sten Madsbad, Kirstine Nyvold Bojsen-Møller
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes, obesity & metabolism 24 (10) (2022)
Chinmay S Marathe, Christopher K Rayner, Karen Louise Jones, Michael Horowitz, Christine Feinle-Bisset, Scott D Standfield, Cong Xie, Carolyn F Deacon, Jens J Holst, Nicolai J Wewer Albrechtsen
Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit. Diabetes, obesity & metabolism 24 (6) (2022)
Juris J Meier, Daniel Robert Quast, Michael A Nauck, Nina Schenker, Carolyn F Deacon, Jens J Holst, Leona Plum-Mörschel, Christoph Kapitza
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, obesity & metabolism 24 (5) (2022)
Rune Ehrenreich Kuhre, Carolyn F Deacon, Nicolai J Wewer Albrechtsen, Jens Juul Holst
Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production? Diabetes, obesity & metabolism 23 (9) (2021)
Maria S Svane, Helle H Johannesen, Christoffer Martinussen, Kirstine N Bojsen-Møller, Martin Lundsgaard Hansen, Adam E Hansen, Carolyn F Deacon, Bolette Hartmann, Sune H Keller, Thomas L Klausen, Annika Loft, Andreas Kjaer, Sten Madsbad, Johan Löfgren, Jens J Holst, Nicolai J Wewer Albrechtsen
No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, obesity & metabolism 22 (10) (2020)
Eelco van Duinkerken, Gabriel Bernardes, Liselotte van Bloemendaal, Dick J Veltman, Frederik Barkhof, Daniel C Mograbi, Victor E A Gerdes, Carolyn F Deacon, Jens J Holst, Madeleine L Drent, Michaela Diamant, Jennifer Ten Kulve, Richard G Ijzerman
Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-en-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI study. Diabetes, obesity & metabolism 23 (2) (2020)
Carolyn F Deacon
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology 16 (11) (2020)
Emilie S Andersen, Asger Lund, Jonatan I Bagger, Camilla Andreasen, Magnus F Grøndahl, Carolyn F Deacon, Bolette Hartmann, Jens J Holst, Filip K Krag Knop, Tina Vilsbøll
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, obesity & metabolism 20 (8) (2018)
Carolyn F Deacon
A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes, obesity & metabolism (2018)